June 1, 2012
Taiho Pharmaceutical announced on May 31 that the company will initiate a global PIII clinical trial for its investigational novel oral anticancer agent TAS-102 in patients with advanced recurrent colorectal cancer who have inadequate responses to standard chemotherapies. The company...read more